Journal of the Korean Pediatric Society 1998;41(2):209-215.
Published online February 15, 1998.
Induction Chemotherapy with BH-AC, Idarubicin, and 6-Thioguanine in Childhood Acute Myelogenous Leukemia
Hyo Jeong Han, Hyoung Jin Kang, Jun Ah Lee, Hyoung Soo Choi, Hyeon Jin Park, Ki Woong Seong, Eun Sun Yoo, Hee Young Shin, Hyo Seop Ahn
Division of Hemato-oncology, Department of Pediatrics, Seoul National University, College of Medicine, Seoul, Korea
소아 급성 골수성 백혈병에서 BH-AC, Idarubicin, 6-Thioguanine 관해유도요법의 치료성적
한효정, 강형진, 이준아, 최형수, 박현진, 성기웅, 유은선, 신희영, 안효섭
서울대학교 의과대학 소아과학교실
Correspondence: 
Hyo Jeong Han, Email: 1
Abstract
Purpose
: We have undertaken this study to evaluate the effects of induction chemotherapy involving BH-AC, idarubicin, and 6-thioguanine(6-TG).
Methods
: BH-AC 300mg/m2/day was administered intravenously over three hours for seven consecutive days. Idarubicin 12mg/m2/day was administered intravenously for three days. 6-TG 100 mg/m2/day was administered orally for seven days. Intrathecal ara-C was administered on the first day of treatment.
Results
: Complete remission(CR) was achieved in 18 cases(66.7%), partial remission(PR) was achieved in 2 cases(7.4%). In previously untreated patients, complete reimission rate was 92.9%(13/ 14), in relapsed patients, 40%(2/5) and in the refractory patients, 37.5%(3/8). The remission duration until December 1996 was 45 to 630 days(median 133). Duration of the neutropenia(ANC<500/μL) was 0 to 38 days(median 24). Side effects were nausea, vomiting(7/27, 25.9%), liver dysfunction(1/27, 3.7%), skin eruption(1/27, 3.7%), and mucositis(1/27, 3.7%). In all cases, fever developed in the neutropenic state(culture proven sepsis in 5 cases). Death occurred in 5 cases who achieved CR due to sepsis after chemotherapy(4 cases), intracerebral hemorrhage after bone marrow relapse (1 case).
Conclusion
: BH-AC, idarubicin, and 6-TG induction chemotherapy could be a useful induction chemotherapy treatment that combines supportive care for infection and bleeding.
Key Words: BH-AC, Idarubicin, Induction chemotherapy, Remission rate, Acute myelogenous leukemia


METRICS Graph View
  • 1,790 View
  • 4 Download


Close layer
prev next